secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001640334-26-000475
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences raises $310k via 12% bridge notes with default conversion feature
--------------------------------------------------------------------------------

- Issued two 12% bridge notes totaling $350,300 principal ($237,300 Vanquish + $113,000 Boot) for net proceeds of $310,000 after $40,300 OID.
- Notes mature Jan 15, 2027; company may prepay at any time with no penalty.
- Upon default, notes can convert into common shares at the higher of $0.125 or 75% of the 10-day VWAP; conversion capped at 4.99% beneficial ownership per holder.
- Proceeds used for general working capital; Company reimbursed Vanquish $10,000 in fees.
- Securities issued under Regulation D, Section 4(a)(2); represented as accredited investors only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer